Karyopharm competitors

Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer. Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry. Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Richard L Feinstein is a VP:Finance/CFO at ENZON PHARMACEUTICALS, INC.; Chief Financial Officer at USA Fitness Corps; and Board Member at USA Fitness Corps and is based in Greater New York City Area. He has worked as VP:Finance/Principal Financial Ofcr at ENZON PHARMACEUTICALS, INC.; Partner at KPMG; and CFO/Consultant at ImageProtect. Richard works or has worked as MEMBER at Association For A Better New York. He studied at Pace University.

Llew Keltner is the co-founder and CEO of [Light Sciences Oncology](https://www.crunchbase.com/organization/light-sciences-oncology), a company that develops light-activated drug products to treat patients with solid tumor cancers. He also works as a consultant at ImmunoVaccine. Prior to that, Keltner held several senior executive positions at AgonOx, MetaStat, Light Sciences Corporation. He also is a director at a number of companies, including Raptor Pharmaceuticals, Infostat, Oregon Life Sciences, LKHealthnet, Goodwell Technologies, RxBazaar, and Gray Peaks. Keltner holds a medical degree and a PhD from Case Western Reserve University.